{
    "clinical_study": {
        "@rank": "11865", 
        "arm_group": {
            "arm_group_label": "CPG 7909 Injection", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "CPG 7909 given alone to patients with renal cell cancer after their nephrectomy.  CPG 7909\n      is as a subcutaneous injection once per week for up to 24 weeks.  Up to 40 patients will be\n      included in the study."
        }, 
        "brief_title": "CPG 7909 in Patients Wih Stage IV Renal Cell Cancer", 
        "completion_date": {
            "#text": "September 2004", 
            "@type": "Actual"
        }, 
        "condition": "Carcinoma, Renal Cell", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Stage IV Renal Cell Carcinoma with lung and/or soft tissue metastasis Nephrectomy\n        Measurable disease by RECIST criteria\n\n        Exclusion Criteria:\n\n        CNS, bone or Liver metastasis Tumors that are mainly papillary, chromophobe, medullary,\n        collecting duct, or unclassified Prior immunotherapy, including IL-2 or IFN-alpha"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 8, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00043407", 
            "org_study_id": "C010", 
            "secondary_id": "CO10, A8501022"
        }, 
        "intervention": {
            "arm_group_label": "CPG 7909 Injection", 
            "description": "In the phase I portion of the protocol, patients will be included in escalating dose groups: 0.08, 0.12, 0.16, 0.36, 0.54 or 0.81 mg/kg of CPG 7909 Injection. Patients will be treated once weekly subcutaneously for 24 weeks.  In the Phase II portion of the trial patients will be treated at the MTD or the highest dose   of 0.81 mg/kg identified in the Phase I dose escalation portion of the trial. All patients in Phase I and Phase II will be treated until disease progression or a maximum of 24 weeks.", 
            "intervention_name": "CPG 7909", 
            "intervention_type": "Drug", 
            "other_name": "PF-03512676"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Renal Cell Carcinoma, Phase I, Phase II, Immunotherapy", 
        "lastchanged_date": "February 11, 2009", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=CO10&StudyName=CPG%207909%20in%20Patients%20wih%20Stage%20IV%20Renal%20Cell%20Cancer"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I/II, Open Label, Multi-Center Study For The Evaluation Of CPG 7909 In Patients With Stage Iv Renal Cell Carcinoma", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "To determine the tolerability of escalating doses of subcutaneously administered CPG 7909 Injection up to a maximum dose of 0.81 mg/kg in patients with metastatic renal cell cancer.", 
                "safety_issue": "No", 
                "time_frame": "Indeterminate"
            }, 
            {
                "measure": "To establish the maximum tolerated dose for CPG 7909 Injection as monotherapy in patients with metastatic renal cell cancer up to a dose of 0.81mg/kg.", 
                "safety_issue": "No", 
                "time_frame": "Indeterminate"
            }, 
            {
                "measure": "To estimate the overall tumor response rate of CpG 7909 according to the RECIST criteria in patients with metastatic renal cell cancer.", 
                "safety_issue": "No", 
                "time_frame": "Indeterminate"
            }
        ], 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00043407"
        }, 
        "responsible_party": {
            "name_title": "Director, Clinical Trial Disclosure Group", 
            "organization": "Pfizer, Inc."
        }, 
        "secondary_outcome": {
            "measure": "To assess tolerability relative to dose exposure, immunologic activity, the pharmacokinetic and pharmacodynamic profile of CPG 7909 Injection, time to progression, duration of response, and time to survival.", 
            "safety_issue": "Yes", 
            "time_frame": "Indeterminate"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2009"
    }, 
    "geocoordinates": {}
}